TG Therapeutics Q1 2024 GAAP EPS $(0.07) Misses $(0.04) Estimate, Sales $63.474M Beat $54.579M Estimate
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics (NASDAQ:TGTX) reported Q1 2024 earnings with a GAAP EPS of $(0.07), missing the $(0.04) estimate by 75%, but saw a significant year-over-year improvement from $(0.28). Sales reached $63.474M, surpassing the $54.579M estimate by 16.30%, and marking a 713.46% increase from the previous year's $7.803M.
May 01, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TG Therapeutics reported a Q1 2024 GAAP EPS of $(0.07), missing estimates, but sales of $63.474M exceeded expectations and showed significant growth from the previous year.
While the EPS miss might concern some investors, the substantial sales beat and year-over-year growth are likely to be viewed positively. The mixed results could lead to neutral short-term stock price movement as investors weigh the EPS miss against the strong sales performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100